AA
EIGR

Ancora Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ancora Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-405
Closed -$241K – 541
2016
Q2 		$241K Sell
405
-40
-9% -$24.3K 0.03% 431
2016
Q1 		$224K Buy
+445
New +$222K 0.03% 428

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ancora Advisors's EIGR Position: Q3 2016 in Review

Ancora Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2016, closing a stake of 405 shares — an estimated $241K sold.

Ancora Advisors first reported a position in EIGR in Q1 2016 and held it in 2 quarters. The position peaked at $241K in Q2 2016. 47 funds tracked by Wall St. Rank hold EIGR as of Q3 2016.

  • Ancora Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Ancora Advisors sold 405 Eiger BioPharmaceuticals, Inc. shares in Q3 2016, an estimated $241K.
  • Ancora Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2016 and held it in 2 quarters.
  • Ancora Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $241K in Q2 2016.
  • 47 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2016.

Based on Ancora Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.